Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b tralokinumab in adults with moderate-to-severe atopic dermatitis
2014-003725-17Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab dose-ranging with Placebo (2 arms). Primary endpoint: Primary: Change from baseline in Eczema Area and Severity Index (EASI) at Week 12. Started Jan 2015; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2014-003725-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003725-17.